Clinical trials: Ramadan Fasting
Type 2 Diabetes Mellitus
Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
To evaluate vildagliptin as compared to gliclazide, given in combination with metformin in Muslim patients with type 2 diabetes fasting during Ramadan.
- Trial name
- STEADFAST (NCT01758380)
- Testing
- Vildagliptin, Gliclazide, Metformin
- Where
- 68 sites in Denmark, Egypt and 14 more
- Volunteers
- 557 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast…
- Trial name
- NCT01340768
- Testing
- Sitagliptin, Sulfonylurea, Metformin
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypothyroidism
Comparing Two-time Points of Thyroid Hormone Replacement During the Holy Month of Ramadan
Muslims all over the world fast during the month of Ramadan from dawn until dusk. There is little data regarding the best timing of levothyroxine intake during the month of Ramadan where taking it on an empty stomach represents a…
- Trial name
- NCT03988517
- Testing
- timing of receiving the drug
- Where
- Qatar
- Volunteers
- 106 people
- Sponsor
- Hamad Medical Corporation
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.
- Trial name
- T-RAM (NCT06635057)
- Testing
- Tirzepatide
- Where
- 29 sites in Saudi Arabia, United Arab Emirates
- Volunteers
- 166 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Insulin Glargine During and After the Period of Fasting in Ramadan
Primary Objectives : To compare the number of hypoglycaemic events (severe, symptomatic, asymptomatic, nocturnal) in patients with type 2 diabetes treated with insulin glargine (Lantus®) and glimepiride (Amaryl®), before, during…
- Trial name
- NCT00258804
- Testing
- Insulin glargine
- Volunteers
- 450 people
- Sponsor
- Sanofi
Type 2 Diabetes
Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN
The purpose of this observational study is to assess effectiveness and tolerability of gliclazide MR 60mg during RAMADAN in a real world setting in 9 countries from Asia Pacific and Middle East/North Africa
- Trial name
- DIA-RAMADAN (NCT04132934)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Servier Affaires Médicales
Diabetes Mellitus, Type 2
O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait
The purpose of the study is to look at the change in blood sugar levels in people with type 2 diabetes who are using oral semaglutide and planning to fast during Ramadan.
- Trial name
- O-SEMA-Fast (NCT05716724)
- Testing
- Semaglutide
- Where
- 20 sites in Kuwait, Saudi Arabia and 1 more
- Volunteers
- 288 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Diabetes Melletus
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders
- Trial name
- ACHIEVE-RAM (NCT07613307)
- Testing
- Orforglipron
- Where
- 40 sites in India, Saudi Arabia and 2 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Hydration Status, Dietary Intake
Comparing an Electrolyte-Carbohydrate Beverage to Water During Ramadan
The purpose of this study is to explore the effects of breaking the fast (iftar) during Ramadan with different beverages on dietary and beverage intake patterns and related measurements during the hours after iftar and into the…
- Trial name
- NCT07429201
- Testing
- Witnessed ad libitum electrolyte-carbohydrate beverage intake over 120 minutes, Witnessed ad libitum water intake over 120 minutes
- Where
- Saudi Arabia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Hypertension
Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients
This is an out-patient based prospective, multi-centre, observational post-marketing surveillance study amongst internists and cardiologists.
- Trial name
- NCT01853839
- Where
- 132 sites in Algeria, Egypt and 3 more
- Volunteers
- 1,674 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
Primary Objective: To compare the safety, in terms of percentage of patients with symptomatic documented hypoglycemia during Ramadan fast, of lixisenatide versus sulfonylurea (SU).
- Trial name
- LixiRam (NCT02941367)
- Testing
- Lixisenatide (AVE0010), Sulfonylurea, metformin
- Where
- 16 sites in India, Israel and 2 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan
The primary purpose of this study is to describe the tolerability of canagliflozin and any sulphonylurea (each administered with metformin with or without a DPP-4 inhibitor), in terms of the percentage of patients with at least…
- Trial name
- CRATOS (NCT02737657)
- Where
- 9 sites in Kuwait, Lebanon and 1 more
- Volunteers
- 379 people
- Sponsor
- Janssen-Cilag International NV
Type 2 Diabetes Mellitus (T2DM)
Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.
- Trial name
- NCT01131182
- Testing
- Sitagliptin phosphate, Comparator: Sulfonylurea, Metformin
- Volunteers
- 1,147 people
- Sponsor
- Merck Sharp & Dohme LLC